Eli Lilly Files Second Quarter 10-Q Report With SEC
The pharmaceutical giant submitted its quarterly financial disclosure as investor attention turns to upcoming dividend and third-quarter results.
Regulatory Filing Submitted
Eli Lilly and Company filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 5, 2026, fulfilling its regulatory disclosure obligations for the second quarter of fiscal 2026. The filing provides investors and analysts with detailed financial information about the pharmaceutical giant's performance during the period.
The Indianapolis-based drugmaker, which commands a market capitalization of approximately $1.04 trillion, closed at $1,169.86 in its most recent trading session. The company has established itself as one of the most valuable pharmaceutical enterprises globally, driven by its portfolio of treatments spanning diabetes, oncology, and immunology.
Upcoming Corporate Events
According to MarginX data, Eli Lilly shareholders have several key dates ahead. The company will distribute a cash dividend of $1.73 per share on August 14, 2026, providing income to investors who held shares as of the record date.
Looking further ahead, the company is scheduled to report third-quarter 2026 results on October 29, placing the earnings announcement between two Federal Open Market Committee rate decisions scheduled for September 16 and October 28. These macroeconomic events could influence market sentiment around healthcare equities and pharmaceutical valuations.
Recent Insider Activity
MarginX data shows recent insider transactions by Melissa Seymour, who exercised stock options totaling 981 shares on two separate occasions. The executive had 438.707 shares withheld for tax purposes in connection with these transactions, a standard practice when employees exercise equity compensation.
Such option exercises are routine corporate activity and typically reflect executives' compensation structure rather than directional views on company performance.
The 10-Q filing represents a standard quarterly disclosure requirement for publicly traded companies, providing transparency into financial condition, results of operations, and material business developments during the reporting period.
This article was generated by MarginX from public news on 2026-08-05. It is not investment advice.